natgillin/translations-raw huggingface dataset:
matching the binarized array of frame sizes obtained in step b) to a number of binary patterns, said binary patterns depicting different GoP structures, whereby each binary pattern contains a repeated basic binary pattern that is characteristic to the GoP structure to be analyzed; 
uspoređivanja binarizirane matrice veličina kadrova dobivene u koraku b) s brojem binarnih uzoraka, gdje navedeni binarni uzorci opisuju različite strukture GoP-a, a svaki binarni uzorak sadrži ponovljeni osnovni binarni uzorak karakterističan za strukturu GoP-a koju treba analizirati;
converting the result of said matching in step c) to form for each binary pattern a single score value; and 
pretvaranja rezultata navedenog uspoređivanja u koraku c) kako bi se za svaki binarni uzorak dobilo jedinstvenu bodovnu vrijednost; i
The method of claims 1 to 3, wherein the reference value is dependant on features of the video stream. 
Postupak u skladu s patentnim zahtjevima 1 do 3, naznačen time što referentna vrijednost ovisi o značajkama video toka.
The method of claim 4, wherein the reference value is dependent on the values of previously captured frame sizes. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što referentna vrijednost ovisi o vrijednostima prethodno digitaliziranih veličina kadrova.
The method of any of the preceding claims, wherein said basic binary patterns depict possible GoP structures for different numbers of consecutive B-frames in frame based coding, field based coding, open GoP coding, or closed GoP coding. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni osnovni binarni uzorci opisuju moguće strukture GoP-a za različite brojeve uzastopnih B-kadrova kod kodiranja na bazi kadrova, kodiranja na bazi polja, kodiranja uz otvorene GoP-ove, ili kodiranja uz zatvorene GoP-ove.
The method of any of the preceding claims, wherein for the matching in step c) the basic binary patterns are repeated with a truncation of the last basic pattern, if the binary pattern of repeated basic binary patterns has not the same length as the number of frames. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se za uspoređivanje u koraku c) osnovni binarni uzorci ponavljaju uz skraćivanje posljednjeg osnovnog uzorka, ako binarni uzorak ponovljenih osnovnih binarnih uzoraka nije jednako dug kao niz kadrova.
The method of any of the preceding claims, wherein in step c) the matching is performed by an element wise exclusive nor or by an element wise exclusive or operation, wherein in step d) the results of every exclusive nor or exclusive or is added up to form the single score value, and wherein in step e) the predefined metric corresponds to the maximum or minimum value, respectively. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se u koraku c) uspoređivanje provodi o elementu ovisnom operacijom Ekskluzivno NILI ili o elementu ovisnom operacijom Ekskluzivno ILI, gdje se u koraku d) rezultate za svako Ekskluzivno NILI ili Ekskluzivno ILI zbraja kako bi se dobilo jedinstvenu bodovnu vrijednost, a u koraku e) prethodno određena metrika odgovara maksimalnoj odnosno minimalnoj vrijednosti.
The method of claim 9, wherein after the estimation of the GoP-pattern a further frame type classification is performed, wherein every subset of consecutive B-frames between two P-frames is further examined as to whether the relation of frame sizes at positions in said subset standing for reference B-frames to frame sizes at all the other positions is larger than a threshold value, which is larger than 1, and wherein, if this is the case for a statistically significant number of said subsets of B-frames in the array of flame sizes, said frames are then assumed to be reference B-frames and the estimated GoP-structure is assumed to be a GoP-structure of a so-called hierarchical coding sequence. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se nakon procjenjivanja uzorka GoP-a provodi daljnje klasificiranje tipova kadrova, gdje se svaki podskup uzastopnih B-kadrova između dva P-kadra dodatno ispituje je li omjer veličina kadrova na položajima u navedenom podskupu koji predstavlja referentne B-kadrove i veličina kadrova na svim drugim položajima veći od granične vrijednosti, koja je veća od 1, te što, ako je to slučaj za statistički značajan broj navedenih podskupova B-kadrova u matrici veličina kadrova, za navedene kadrove se zatim pretpostavlja da su referentni B-kadrovi, a za procijenjenu strukturu GoP-a se pretpostavlja da je struktura GoP-a tzv. hijerarhijskog kodnog niza.
A method for estimating the type of the Group of Picture, GoP, structures of a plurality of video frames in a video stream by estimating their frame types, comprising the steps of: 
Postupak procjenjivanja tipa struktura skupine slika, GoP, za više video kadrova u video toku procjenjivanjem tipova njihovih kadrova, naznačen time što se sastoji u koracima:
capturing the frame sizes in byte of every video frame n subsequent to an initial I-frame into a multiple of arrays, by exploiting features of the transport layer carrying the video stream, where each array of these multiple arrays has a different size, ArraySize[BP], equal to the length of the basic frame type pattern, BP, of each considered GoP structure, where the size of each frame n is added up in the n % ArraySize[BP]'th element of each array, Array[BP], and where the number of frame sizes added to every element of every array is noted, which is depicted by the following symbolic code: so that only for that specific array, representing the true GoP-structure of the video stream, P-frames are always added up with P-frames and B-frames are always added up with B-frames; 
digitaliziranja veličina kadrova u bajtu svakog video kadra n koji dolazi nakon početnog I-kadra u više matrice, iskorištavanja značajki transportnog sloja koji nosi video tok, gdje svaka matrica od tih više matrica ima različitu veličinu, ArraySize[BP], jednaku duljini osnovnog uzorka tipa kadrova, BP, za svaku razmatranu strukturu GoP-a, gdje se veličinu svakog kadra n pribraja u n % ArraySize[BP]-ti element svake matrice, Array[BP], te gdje se bilježi broj veličina kadrova pribrojanih u svaki element svake matrica, što opisuje sljedeći simbolički kod: [image] tako da se samo za tu specifičnu matricu, koja predstavlja pravu strukturu GoP-a videotoka, P-kadrove uvijek zbraja s P-kadrovima, a B-kadrove se uvijek zbraja s B-kadrovima;
calculating the relation between assumed P-frames and averaged assumed B-frames for open GoP coding as well as for closed GoP coding for all the arrays 'BP' of step b), wherein in step c) for every array two relation values are produced as described below to be able to decide between open GoP and closed GoP coding: 
izračunavanja odnosa između pretpostavljenih P-kadrova i prosjeka pretpostavljenih B-kadrova za kodiranje uz otvorene GoP-ove, kao i za kodiranje uz zatvorene GoP-ove za sve matrice "BP" u koraku b), gdje se u koraku c) za svaku matricu dvije vrijednosti odnosa dobiva kao što je opisano niže, kako bi se omogućilo razlučivanje između kodiranja uz otvorene GoP-ove i kodiranja uz zatvorene GoP-ove:
if the examined video stream comprises open GoP coding, the assumed P-frame of the basic pattern that each of the arrays BP represent, would be located in the last element of said arrays BP and all other elements of said arrays would be occupied by B-frames so that the relation Ro for open GoP coding streams is calculated as the last array element divided by the average of all other array elements, with the symbolic code: 
ako ispitivani video tok ima kodiranje uz otvorene GoP-ove, pretpostavljeni P-kadar u osnovnom uzorku kojeg predstavlja svaka od matrica BP, bi se nalazio u posljednjem elementu navedenih matrica BP, a svi drugi elementi navedenih matrica bili bi zauzeti B-kadrovima, tako da se omjer RO za tokove s kodiranjem uz otvorene GoP-ove izračunava kao posljednji element matrice podijeljen s prosječnom vrijednošću za sve druge elemente matrice, uz simbolički kod:
ArraySize[BP]-2 or ii) if the examined video stream comprises closed GoP coding, the assumed P-frame of the basic pattern that each of the arrays BP represent, is located in the first element of said arrays BP and all other elements of said arrays would be occupied by B-frames so that the relation Rc for closed GoP coding streams is calculated as the first array element divided by the average of all other array elements, with the symbolic code: 
[image] ili ii) ako ispitivani video tok ima kodiranje uz zatvorene GoP-ove, pretpostavljeni P-kadar u osnovnom uzorku kojeg predstavlja svaka od matrica BP, se nalazi u prvom elementu navedenih matrica BP, a svi drugi elementi navedenih matrica bili bi zauzeti B-kadrovima, tako da se omjer RC za tokove s kodiranjem uz zatvorene GoP-ove izračunava kao prvi element matrice podijeljen s prosječnom vrijednošću za sve druge elemente matrice, uz simbolički kod:
determining the particular array, which has the largest relation between assumed P-frames and assumed averaged B-frames among all the calculated relations for open GoP coding and closed GoP coding, and determining the GoP structure associated with the particular array. 
određivanja pojedine matrice koja ima najveći omjer između pretpostavljenih P-kadrova i pretpostavljenih uprosječenih B-kadrova među svim izračunatim omjerima za kodiranje uz otvorene GoP-ove i kodiranje uz zatvorene GoP-ove, te određivanja strukture GoP-a povezane s pojedinom matricom.
The method of claim 12, wherein the number of frames n, comprises all frames until the next Intra-frame. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što niz kadrova n sadrži sve kadrove do sljedećeg Intra-kadra.
The method of any of the claims 12 to 13, wherein the GoP-structure associated with the determined array according to step d) is chosen to be the valid estimation of the GoP-pattern, field/frame status and open GoP/closed GoP status of the currently analysed series of frames. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 12 do 13, naznačen time što se strukturu GoP-a povezanu s određenom matricom u skladu s korakom d) tako bira ta bude važeće procjenjivanje uzorka GoP-a, status polja/kadra i otvoreni GoP/zatvoreni GoP status trenutno analiziranih nizova kadrova.
The method of claim 14, wherein after the estimation of the GoP-pattern a further frame type classification is performed wherein the subset of B-frames in the array representing the estimated GoP-structure according to step d) is examined as to whether the relation of frame sizes at positions in said subset standing for reference B-frames to frame sizes at all the other positions is larger than a threshold value, which is larger than 1, and wherein, if this is the case, said frames are then assumed to be reference B-frames and the estimated GoP-structure is assumed to be a GoP-structure of a so called hierarchical coding sequence. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što se nakon procjenjivanja uzorka GoP-a provodi daljnje klasificiranje tipova kadrova, gdje se podskup B-kadrova u matrici koja predstavlja procijenjenu strukturu GoP-a u skladu s korakom d) ispituje je li omjer između veličina kadrova na položajima u navedenom podskupu koji predstavlja referentne B-kadrove i veličine kadrova na svim drugim položajima veći od granične vrijednosti, koja je veća od 1, te gdje se, ako je to slučaj, za navedene kadrove zatim pretpostavlja da su referentni B-kadrovi, a za procijenjenu strukturu GoP-a se pretpostavlja da je struktura GoP-a tzv. hijerarhijskog kodnog niza.
reacting a compound of Formula III or its stereoisomers thereof, wherein P1 is hydrogen or a protecting group and L is a leaving group, with a substituted or unsubstituted purine or pyrimidine base defined above, in the presence of a Lewis acid with the proviso that the Lewis acid does not contain any silyl group, to obtain a compound of Formula IV or its stereoisomers thereof, wherein P1 is hydrogen or a protecting group and R2 is a substituted or unsubstituted purine or pyrimidine base defined above, 
reagiranja spoja Formule III ili njegovih stereoizomera, [image] gdje je P1 vodik ili zaštitna skupina a L je odlazeća skupina, sa gore definiranom supstituiranom ili nesupstituiranom bazom purina ili pirimidina, u nazočnosti Lewisove kiseline pod uvjetom da Lewisova kiselina ne sadrži bilo koju skupinu silila, kako bi se dobio spoj Formule IV ili njegovi stereoizomeri, [image] gdje je P1 vodik ili zaštitna skupina a R2 je gore definirana supstituirana ili nesupstituirana baza purina ili pirimidina,
isolating the compound of Formula I or its stereoisomers, and salts thereof, from the reaction mixture thereof. 
izoliranja spoja Formule I ili njegovih stereoizomera, te njegovih soli iz njegove reakcijske smjese.
A process for the preparation of lamivudine of Formula I (A) or a compound of Formula I (C), or mixtures thereof wherein the process comprises, 
Postupak priprave lamivudina Formule I (A) ili spoja Formule I (C) ili njihovih smjesa [image] naznačen time, da se postupak sastoji od,
reducing the compound of Formula IV (A) or Formula IV (B), or mixtures thereof, to obtain lamivudine of Formula I (A) or the compound of Formula I (C), or mixtures thereof, and 
reduciranja spoja Formule IV (A) ili Formule IV (B) ili njihovih smjesa, kako bi se dobio lamivudine Formule I (A) ili spoj Formule I (C) ili njihove smjese, i
isolating lamivudine of Formula I (A) or the compound of Formula I (C), or mixtures thereof, from the reaction mixture. 
izoliranja lamivudina Formule I (A) ili spoja Formule I (C) ili njihovih smjesa iz reakcijske smjese.
A process according to claim 6, wherein the chiral auxiliary P1 of the compound of Formula III (A) or Formula III (B), or mixtures thereof, and that of the compound of Formula IV (A) or Formula IV (B), or mixtures thereof is an L-menthyl group. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time, da je kiralni pomoćni Pi spoja Formule III (A) ili Formule III (B) ili njihovih smjesa i da spoj Formule IV (A) ili Formule IV (B) ili njihovih smjesa je L-mentilna skupina.
separating a compound of Formula IV (A) from the reaction mixture thereof, wherein P1 is a chiral auxiliary and R2 is cytosine, wherein the amino or hydroxy, or both the groups of said cytosine are unprotected or protected with protecting groups, 
razdvajanja spoja Formule IV (A) od njegove reakcijske smjese, [image] gdje je P1 kiralni pomoćni a R2 je citozin, pri čemu su amino ili hidroksi, ili obje skupine rečenog citozina nezaštićene ili zaštićene zaštitnim skupinama,
reducing the compound of Formula IV (A), and 
reduciranja spoja Formule IV (A), i
isolating lamivudine of Formula I (A) from the reaction mixture thereof. 
izoliranja lamivudina Formule I (A) iz njegove reakcijske smjese.
A process according to claim 11, wherein the compound of Formula IV (A) is separated in step b) by treating the compound of Formula IV (C) with a solvent, which selectively dissolves the undesired isomers while the compound of Formula IV (A) is partially or completely insoluble in said solvent. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da je spoj Formule IV (A) separiran u koraku b) tretiranjem spoja Formule IV (C) s otapalom, koji selektivno otapa neželjene izomere dok je spoj Formule IV (A) djelomično ili potpuno netopiv u rečenom otapalu.
A process according to claim 15, wherein the solvent is methanol or isopropyl acetate, or a mixture thereof. 
Postupak u skladu s patentnim zahtjevom 15, naznačen time, da je otapalo metanol ili izopropil acetat ili njihova smjesa.
An inserter according to claim 1, characterised in that the flange (4) is arranged to at least partially protect the intrauterine system before its insertion. 
Naprava za uvođenje prema zahtjevu 1, naznačena time da je prirubnica (4) postavljena tako da barem djelomično štiti intrauterini sustav prije njegovog umetanja.
An inserter according to claim 1 or 2, characterised in that the the means for locking the slider (5) comprises a self-locking button movable in a stepwise way. 
Naprava za uvođenje prema zahtjevu 1 ili 2, naznačena time da sredstva za zaključavanje klizača (5) sadrže samo-zaključavajuće dugme koje je pomično u stepenastnim koracima.
The use according to any one of the preceding claims, wherein the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril,benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate,temocapril, trandolapril, trandolaprilat,ceranapril, moexipril, quinaprilat and spirapril or a pharmaceutically acceptable derivative thereof. 
Pimobendan prema bilo kojem od prethodnih zahtjeva, naznačen time, da je ACE inhibitor odabran iz skupine koju čine omapatrilat, MDL100240, alacepril, benazepril, kaptopril, silazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lizinopril, perindopril, kvinapril, ramipril, ramiprilat, saralazin acetat, temokapril, trandolapril, trandolaprilat, ceranapril, moeksipril, kvinaprilat i spirapril.
and R27 independently represent H, C1-6 alkyl, C3-7cycloalkyl or heterocyclyl R29 and R30 independently represent H, C1-6alkyl optionally substituted by OH; and R3 together with the nitrogen atom to which they are attached may form a heterocyclyl ring; 
i R27 neovisno predstavljaju H, C1-6alkil, C3-7cikloalkil ili heterociklil; i R30 neovisno predstavljaju H, C1-6alkil, izborno supstituiran s OH; i R8, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten;
Use of the pharmaceutical composition according to any one of claims 1 to 12 as an anti-cancer vaccine. 
Uporaba farmaceutskog sastava prema bilo kojem zahtjevu 1 do 12 kao cjepiva protiv raka. Komplet koji sadrži:
a container containing a pharmaceutical composition according to any of claims 1 to 13, in solution or in lyophilized form; 
posudu koja sadrži farmaceutski sastav prema bilo kojoj zahtjevu 1 do 13, u otopini ili u liofiliziranom obliku;
a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof. 
njegov stereoizomer, enantiomer ili tautomer, njegova farmaceutski prihvatljiva sol, ili njegov farmaceutski sastav.
each R12 is independently selected from hydrogen or C1-C6alkyl; provided, however, that R2 can not be pyrazinyl, pyridinonyl, pyrrolidinonyl or imidazolyl; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof. 
je vodik ili C1-C3alkil; i svaki R12 je neovisno odabran od vodika ili C1-C6alkila; međutim uz uvjet da R2ne može biti pirazinil, piridinonil, pirolidinonil ili imidazolil; njegov stereoizomer, enantiomer ili tautomer, njegova farmaceutski prihvatljiva sol, ili njegov farmaceutski sastav.
A method of predicting whether a patient is at increased risk of hypertension associated with treatment with a VEGF antagonist, comprising screening a sample isolated from said patient for a genomic polymorphism at VEGF (-1498C/T), wherein the patient is at increased risk of hypertension associated with treatment with a VEGF antagonist if the corresponding genotype comprises VEGF (-1498C). 
Postupak predviđanja da li je kod pacijenta povećan rizik za hipertenziju povezan s liječenjem VEGF (vaskularni endotelijski faktor rasta stanice) antagonistom, naznačen time, da obuhvaća snimanje uzorka izoliranog iz spomenutog pacijenta za genomski polimorfizam na VEGF (-1498C/T), pri čemu pacijent ima povećani rizik za hipertenziju povezan s liječenjem VEGF antagonistom, ako odgovarajući genotip sadrži VEGF (-1498C).
Alfuzosine or its pharmaceutically acceptable salts for use according to claim 1, wherein said inflammatory bladder results from or is associated with interstitial cystitis. 
Alfuzosin, ili njegove farmaceutski prihvatljive soli, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedena upala mokraćnog mjehura posljedica ili je povezana s intersticijskim cistitisom.
The compound according to claim 1, wherein R is methyl; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R je metil;
and R2, independently of each other, are hydrogen, methyl or CF3; 
i R2 su, međusobno neovisno, vodik, metil ili CF3;
A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof or an enantiomer or a diastereomer thereof in combination with at least one pharmaceutically acceptable excipient, diluent or a carrier. 
Farmaceutski pripravak, naznačen time što sadrži spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegovu farmaceutski prihvatljivu sol ili enantiomer ili dijastereomer, u kombinaciji s najmanje jednom farmaceutski prihvatljivom pomoćnom tvari, razrjeđivačem ili podlogom.
The use according to claim 5, wherein the sleep disorder is selected from the group consisting of narcolepsy, circadian rhythm sleep disorder, obstructive sleep apnea, periodic limb movement and restless leg syndrome, excessive sleepiness and drowsiness due to medication side-effect. 
Upotreba u skladu s patentnim zahtjevom 5, naznačena time što poremećaj spavanja se bira iz skupine koju čine narkolepsija, poremećaj dnevnog ritma spavanja, opstruktivna apneja u snu, periodični pokreti udova i sindrom nemirnih nogu, prekomjerna pospanost i snenost kao nuspojava uzimanja medikamenta.
The pirfenidone for use of claim 1 or use of claim 2 wherein the patient is a patient who has discontinued use of fluvoxamine prior to the initiation of pirfenidone therapy in order to avoid reduced clearance of or increased exposure to pirfenidone. 
Pirfenidon za upotrebu prema zahtjevu 1 ili upotrebu prema zahtjevu 2, naznačen time što je pacijent, pacijent koji je prekinuo upotrebu fluvoksamina prije početka pirfenidonske terapije u cilju izbjegavanja smanjenog klirensa ili povećanog izlaganja pirfenidonu.
The pirfenidone for use or use of claim 4, wherein the patient has discontinued administration of fluvoxamine within 1 month prior to starting pirfenidone therapy. 
Pirfenidon za upotrebu ili upotreba prema zahtjevu 4, naznačen time što je pacijent prekinuo uzimanje fluvoksamina u toku 1 mjeseca prije početka pirfenidonske terapije.
The pirfenidone for use or use of claim 4, wherein the patient has discontinued administration of fluvoxamine within 2 weeks prior to starting pirfenidone therapy. 
Pirfenidon za upotrebu ili upotreba prema zahtjevu 4, naznačen time što je pacijent prekinuo uzimanje fluvoksamina u toku 2 tjedna prije početka pirfenidonske terapije.
wherein said peptides show a solubility in 90% acetic acid of at least 2.7 mg/mL; 
gdje spomenuti peptidi pokazuju topivost u 90%-tnoj octenoj kiselini od najmanje 2,7 mg/mL;
R1a is selected from the group consisting of hydrogen, C1-C6alkyl and C3-C15cyloalkyl; 
a je odabran iz skupine koju čine vodik, C1-C6alkil i C3-C15cikloalkil;
The compound of Claim 63 selected from the group consisting of the following: 
Spoj prema zahtjevu 63, naznačen time, da je odabran iz skupine koju čine sljedeći:
is C3-C12hydroxyalkyl unsubstituted or substituted with one or more halo groups; 
je C3-C12hidroksialkil nesupstituiran ili supstituiran jednom ili više halo skupina;
The compound of Claim 14 selected from the group consisting of the following: 
Spoj prema zahtjevu 14, naznačen time, da je odabran iz skupine od sljedećih:
The compound of Claim 21 selected from the group consisting of the following: 6-[4-(2-Nitrobenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (3-methylbutyl)amide; 
Spoj prema zahtjevu 21, naznačen time, da je odabran iz skupine koju čine sljedeći: -[4-(2-nitrobenzoil)piperazin-1-il]piridazin-3-karboksilna kiselina (3-metilbutil)amid;
The compound of Claim 27 selected from the group consisting of the following: 6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (2-ethoxyethyl)amide; 
Spoj prema zahtjevu 27, naznačen time, da je odabran iz skupine koju čine sljedeći: -[4-(2-trifluorometilbenzoil)piperazin-1-il]piridazin-3-karboksilna kiselina (2-etoksietil)amid;